Announcements Trials
Browse Landscape

Phase

Phase NA 79Phase 2 30Phase 3 19Phase 1/2 5Phase 2/3 4Phase 1 4Phase 4 2

Status

Recruiting 5Withdrawn 2Unknown 2Completed 2Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 2Other solid neoplasm 1Head & Neck 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Renal Insufficiency 1Progressive Metastatic Castrate Resistant Prostate Cancer 1Kidney Failure, Chronic 1Carcinoma, Renal Cell 1Breast Neoplasms 1Advanced/Metastatic Solid Tumors 1

Interventions

pembrolizumab 109Cyclophosphamide 85fludarabine 67Carboplatin 59Injections 58Bevacizumab 52Specimen Handling 42Gemcitabine 41Paclitaxel 40Magnetic Resonance Spectroscopy 40venetoclax 38Nivolumab 38Cisplatin 37Dexamethasone 35Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Oxaliplatin 26Capecitabine 26Pemetrexed 25Fluorouracil 25toripalimab 24abemaciclib 24Irinotecan 24Azacitidine 24Fulvestrant 23Rituximab 21fludarabine phosphate 20durvalumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Standard of Care × Clear all
NCT06502691 2026-05-19

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

University of Washington

Phase 1/2 Recruiting
22 enrolled
Breast

Breast Neoplasms

NCT07206056 2026-05-08

TulmiSTAR-01

Novartis

Phase 1/2 Recruiting
188 enrolled
Genitourinary

Progressive Metastatic Castrate Resistant Prostate Cancer

NCT06097468 2026-04-13

Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)

University of California, San Francisco

Phase 1/2 Recruiting
40 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05405595 2026-01-07

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Adagene Inc

Phase 1/2 Recruiting
186 enrolled
Other solid neoplasm

Advanced/Metastatic Solid Tumors

NCT07053462 2025-07-08

CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Failure, Chronic, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡